Vulvovaginal Candidiasis Market Pipeline Market Research Report 2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Vulvovaginal Candidiasis – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.

The “Vulvovaginal Candidiasis – Pipeline Insight, 2022” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Vulvovaginal Candidiasis pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The assessment part of the report embraces, in depth Vulvovaginal Candidiasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vulvovaginal Candidiasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

Companies and academics are working to assess challenges and seek opportunities that could influence Vulvovaginal Candidiasis R&D. The therapies under development are focused on novel approaches to treat/improve Vulvovaginal Candidiasis.

Vulvovaginal Candidiasis Emerging Drugs Chapters

This segment of the Vulvovaginal Candidiasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vulvovaginal Candidiasis Emerging Drugs

Oteseconazole: Mycovia Pharmaceuticals

Oteseconazole (VT-1161) is a novel, investigational oral therapy for the treatment of recurrent vulvovaginal candidiasis (RVVC). Oteseconazole is designed with the goal of having greater selectivity, fewer side effects and improved efficacy as compared with currently available antifungal agents.

Oteseconazole received FDA Qualified Infectious Disease Product and Fast-Track designations and, if approved, could be the first FDA-approved treatment for RVVC. Mycovia Pharmaceutical announced the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for oteseconazole, an oral antifungal product for the treatment of recurrent vulvovaginal candidiasis (RVVC).

MAT2203: Matinas BioPharma

MAT2203 is an oral and non-toxic encochleated form of amphotericin B (CAmB). This antifungal drug is the primary broad-spectrum treatment for immunocompromised patients. Unlike some other therapies, it doesn’t simply stop fungus from growing, but kills it entirely. The drug is currently in phase 2 stage of development for the treatment of Vulvovaginal Candidiasis.

Benzydamine/econazole: Angelini Pharmaceuticals

Angelini Pharmaceuticals is developing an antimycotic vaginal pessary combination comprising benzydamine hydrochloride 6mg and econazole nitrate 150mg in the Treatment of uncomplicated vulvovaginal Candidiasis.

To assess the microbiological and clinical efficacy, the safety and acceptability of the benzydamine HCl 6 mg and econazole nitrate 150 mg vaginal pessary, in comparison to Pevaryl 150 mg vaginal pessary, in the treatment of uncomplicated VVC. Currently, the drug is in Phase 3 stage of development for the treatment of Vulvovaginal Candidiasis.

Miconazole/Domiphen Bromide: Hyloris Pharmaceuticals

MCZ-DB is a locally applied vaginal cream, and based on promising results from preclinical studies, it is believed that it could have significant potential in recurring VVC infections, an underserved condition for which there are no locally administered topical therapies currently available. Miconazole-Domiphen Bromide is being developed in Phase 2 stage of development, in partnership with Purna Female Health (PFH).

Vulvovaginal Candidiasis: Therapeutic Assessment

This segment of the report provides insights about the different Vulvovaginal Candidiasis drugs segregated based on the following parameters that define the scope of the report, such as:

Major Players in Vulvovaginal Candidiasis

There are approx. 7+ key companies which are developing the therapies for Vulvovaginal Candidiasis. The companies which have their Vulvovaginal Candidiasis drug candidates in the most advanced stage, i.e. Pre-Registration include, Mycovia Pharmaceuticals.

Key Players

• Mycovia Pharmaceuticals
• Matinas BioPharma
• NovaDigm Therapeutics
• Toltec Pharmaceuticals
• LTN Pharm
• ProFem
• Ferrer
• Mariposa Health

Key Products

• Oteseconazole
• MAT2203
• NDV 3
• Benzydamine/econazole
• Miconazole/Domiphen Bromide
• TOL 463

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/u7y6m9

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900